title: P2Y12 platelet receptors: importance in percutaneous coronary intervention.
abstract: Apart from their role in hemostasis and thrombosis, platelets are involved in many other biological processes such as wound healing and angiogenesis. Percutaneous coronary intervention is a highly thrombogenic procedure inducing platelets and monocytes activation through endothelial trauma and contact activation by intravascular devices. Platelet P2Y12 receptor activation by adenosine diphosphate facilitates non-ADP agonist-mediated platelet aggregation, dense granule secretion, procoagulant activity, and the phosphorylation of several intraplatelet proteins, making it an ideal drug target. However, not all compounds that target the P2Y12 receptor have similar efficacy and safety profiles. Despite targeting the same receptor, the unique pharmacologic properties of each of these P2Y12 receptor-directed compounds can lead to very different clinical effects.
authors.forename: Felipe Jose de Andrade
authors.initials: FJ
authors.lastname: Falcão
authors.forename: Leonardo
authors.initials: L
authors.lastname: Carvalho
authors.forename: Mark
authors.initials: M
authors.lastname: Chan
authors.forename: Cláudia Maria Rodrigues
authors.initials: CM
authors.lastname: Alves
authors.forename: Antônio Carlos Camargo
authors.initials: AC
authors.lastname: Carvalho
authors.forename: Adriano Mendes
authors.initials: AM
authors.lastname: Caixeta
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000249:Adenosine Monophosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D062645:Percutaneous Coronary Intervention; D010879:Piperazines / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D000068799:Prasugrel Hydrochloride; D058921:Purinergic P2Y Receptor Antagonists / Q000494:pharmacology*; D058925:Receptors, Purinergic P2Y12 / Q000187:drug effects*; D058924:Thienopyridines / Q000494:pharmacology; D013876:Thiophenes / Q000494:pharmacology; D000077486:Ticagrelor
chemical_list: D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D058924:Thienopyridines; D013876:Thiophenes; D000249:Adenosine Monophosphate; C117446:cangrelor; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine
references.citation: Int J Cardiol. 2011 Aug 4;150(3):325-31
references.pmid: 20828843
references.citation: Heart Lung Circ. 2007;16 Suppl 3:S17-28
references.pmid: 17611155
references.citation: J Am Coll Cardiol. 2012 Jul 17;60(3):193-9
references.pmid: 22789884
references.citation: J Am Coll Cardiol. 2013 Feb 19;61(7):723-7
references.pmid: 23312702
references.citation: JAMA. 2012 Nov 7;308(17):1785-94
references.pmid: 23117779
references.citation: Lancet. 2001 Aug 18;358(9281):527-33
references.pmid: 11520521
references.citation: JAMA. 2011 Mar 16;305(11):1097-105
references.pmid: 21406646
references.citation: N Engl J Med. 2009 Dec 10;361(24):2318-29
references.pmid: 19915221
references.citation: Circulation. 2010 Mar 16;121(10):1188-99
references.pmid: 20194878
references.citation: J Am Coll Cardiol. 2010 Jun 8;55(23):2556-66
references.pmid: 20513595
references.citation: N Engl J Med. 2009 Sep 10;361(11):1045-57
references.pmid: 19717846
references.citation: JAMA. 2012 Jan 18;307(3):265-74
references.pmid: 22253393
references.citation: Pharmacol Ther. 2005 Nov;108(2):180-92
references.pmid: 15955565
references.citation: Annu Rev Pharmacol Toxicol. 2006;46:277-300
references.pmid: 16402906
references.citation: Circulation. 2012 Mar 13;125(10):1276-87; discussion 1287
references.pmid: 22412089
references.citation: JAMA. 2005 Sep 14;294(10):1224-32
references.pmid: 16143698
references.citation: Thromb Haemost. 2011 May;105 Suppl 1:S13-33
references.pmid: 21479340
references.citation: J Am Coll Cardiol. 2010 Sep 14;56(12):919-33
references.pmid: 20828644
references.citation: Acute Card Care. 2011 Jun;13(2):68-75
references.pmid: 21517669
references.citation: Circulation. 2010 Jan 5;121(1):171-9
references.pmid: 20048234
references.citation: Blood Rev. 2011 Jul;25(4):155-67
references.pmid: 21496978
references.citation: N Engl J Med. 2012 Nov 29;367(22):2100-9
references.pmid: 23121439
references.citation: J Thromb Thrombolysis. 2009 Oct;28(3):366-80
references.pmid: 19597766
references.citation: N Engl J Med. 2009 Dec 10;361(24):2330-41
references.pmid: 19915222
references.citation: Am Heart J. 2007 Aug;154(2):221-31
references.pmid: 17643570
references.citation: N Engl J Med. 2007 Nov 15;357(20):2001-15
references.pmid: 17982182
references.citation: Am Heart J. 2011 Jan;161(1):1-4
references.pmid: 21167333
references.citation: Ann Intern Med. 2012 Mar 20;156(6):445-59
references.pmid: 22431677
references.citation: Circulation. 2004 Nov 9;110(19):e489-93
references.pmid: 15533872
references.citation: J Am Coll Cardiol. 2012 Jun 12;59(24):2159-64
references.pmid: 22520250
references.citation: J Thromb Haemost. 2003 Jun;1(6):1133-5
references.pmid: 12871307
references.citation: Circulation. 2009 Dec 22;120(25):2577-85
references.pmid: 19923168